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Abstract
OBJECTIVE: To investigate the neuroprotective
mechanism of combination extract of Renshen
(Panax Ginseng), Yinyanghuo (Herba Epimedii Brevi-
cornus), Yuanzhi (Radix Palygalae) and Jianghuang
(Rhizoma Curcumae Longae) (GEPT) in treating Al-
zheimer's disease on the target of glycogen syn-
thase kinase 3β (GSK-3β).
METHODS: Three-month-old APPV717I transgenic
mice were randomly divided into ten groups (n=12
per group) and intragastrically administrated vehi-
cle or medicines: APP group was given 0.5% CMC,
donepezil group was given donepezil (APP + D
group) (0.92 mg/kg-1·day-1), and GEPT groups were
given small dose of GEPT (APP+Gs group) (0.075 g/
kg-1·day-1), medium dose (APP+Gm group) (0.15 g/
kg-1·day-1), and large dose (APP+Gl group) (0.30 g/
kg-1 · day-1) for 4 or 8 months, respectively.
Three-month-old C57BL/6J mice as vehicle controls
(n=12) were given 0.5% CMC for 4 or 8 months as
well. The GSK-3β expression in the cortex of 7- and
11-month-old APPV717I transgenic mice with and
without GEPT or donepezil treatment and normal
C57BL/6J mice were measured via Western blotting
and Immunohistochemistry.
RESULTS: Immunohistochemistry analysis showed
significant increase of GSK-3β in the cerebral cortex
of 7-month-old APP group (compare to control
group P=0.003), while the GSK-3β expression of
donepezil or GEPT group were all significantly de-
creased (Donepezil vs APP: P=0.041; Gl vs APP: P=
0.049; Gm vs APP: P=0.029; Gh vs APP: P=0.036).
Western blot analysis showed similar results. The
densitometric measures of GSK-3β in APP mice in-
creased significantly as compared with the control
group (P=0.008). And the GSK-3β expression in
211
JTCM |www. journaltcm. com April 15, 2013 |volume 33 | Issue 2 |
Shi J et al. / Experimental Study
donepezil and GEPT groups were all decreased.
There was significant difference between Gh group
or donepezil group and the control group (P=0.05).
Similar findings were shown in the 11-month-old
mice in each group, except for greater decrease of
GSK-3β in the GEPT group.
CONCLUSION: GEPT can effectively decrease the
level of GSK-3β expression in the brain cortex of AP-
PV717I transgenic mice, and such effect is more sig-
nificant in 11-month-old mice. This partially ex-
plains the neuroprotecting mechanism of GEPT in
preventing and treating of AD.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Alzheimer's disease (AD) is the most common progres-
sive neurodegenerative disorder, affecting approximate-
ly 26 million patients worldwide up to 2006.1 Neurofi-
brillary tangles, are composed of hyperphosphorylated
microtubule-associated protein tau (MAPT), and se-
nile plaques, accumulation of β-amyloid peptides, are
two key neuropathological and diagnostic features of
AD. While glycogen synthase kinase 3 (GSK-3), a
45-kDa, constitutively active, proline-directed serine/
threonine kinase has garnered significant attention in
the research of AD and other neurodegenerative diseas-
es. It is expressed ubiquitously and found at high levels
in the brain where it localizes predominantly to neu-
rons, participates in a number of physiological process-
es, such as cell structure, metabolism, gene expression
and apoptosis.2, 3 GSK-3 also plays a pivotal and central
role in the pathogenesis of AD. There was a 'GSK-3 hy-
pothesis of AD' recently formulated4 and it is a possi-
ble link between beta amyloid peptide and tau protein.
In various cell culture, invertebrate and mammalian
APPs of AD, over activity of GSK-3 leads to the hyper-
phosphorylation of tau, increased generation of amy-
loid-β (Aβ) and deficiency of learning and memory
function.5-7 More preciously, GSK-3β can phosphory-
late numerous sites on tau and significantly impair its
ability to bind microtubules. It may also play a role in
regulating the degradation of tau8 and the formation of
insoluble tau fibrils9. Importantly, inhibiting GSK-3 ac-
tivity can relieve the accumulation of Aβ peptides and
the formation of hyperphosphorylated insoluble tau fi-
brils in the best available APPs of AD,7,10-12 thus offers a
new target to the treatment of AD.
As for the treatment of AD, a few fulfilled the ultimate
disease-modifying goal. Neither cholinesterase inhibi-
tors, nor the currently available N-methyl-d-aspartate
receptor antagonist memantine are disease-modifying
treatments. And the current evidences supporting the
use of single herbs or herbal formulations is inconclu-
sive or inadequate13 and herbal mixtures may have ad-
vantages in treating AD with their multiple targets reg-
ulation.
GEPT, a combination of herbal extracts, also called
GETO (Compound Jinsiwei) in our previous papers,
consists of four active components from Renshen
(Panax Ginseng), Yinyanghuo (Herba Epimedii Brevicor-
nus), Yuanzhi (Radix Palygalae) and Jianghuang (Rhi-
zoma Curcumae Longae).14 Previous studies have proved
that GEPT extract can markedly enhance learning and
memory of AD rat APP induced by hippocampal injec-
tion of Aβ1-42 peptide or induced by intravenous in-
jection of Aβ 1-40 peptide,15 and reduce the level of
Aβ in APPV717I transgenic mice via the inhibition ofγ-secretase (presenilin-1) and the promotion of insulin
degrading enzyme and neprilysin.14 Moreover, GEPT
also showed significant improvement on cognitive func-
tion in patients with amnestic mild cognitive impair-
ment, an early stage of AD (n=101), consistently across
different cognitive scales in a 24-week preliminary clini-
cal study.16 However, the GSK-3 inhibiting effects of
GEPT in APP mice is still unknown. This study there-
fore will investigate the mechanism of GEPT on pre-
venting and treating AD from the target of GSK-3β.
MATERIALS ANDMETHODS
Drugs preparation
GEPT was provided by Henan Wanxi Pharmaceutical
Company Limited (Batch No.: 20010923) and dissolved
in 0.5% carboxymethyl cellulose (CMC) at concentra-
tion of 30 mg/mL. Hydrochloric acid donepezil tablets
were provided by Eisai (China) Pharmaceutical Compa-
ny Limited (Batch No.: 090508A), crashed and dissolved
into 0.5%CMCat concentration of 0.092mg/mL.
Animals and medicine administration
Three-month-old APPV717I mice (C57BL/6J mice
carrying mutated human APP-CT100 containing the
London mutation V717I) and C57BL/6J mice
(non-transgenic inbred mice, as vehicle controls), both
half male and half female, were purchased from the In-
stitute of Experimental Animals, Chinese Academy of
Medical Sciences & Peking Union Medical College
(Beijing, China). All animals were housed in the Phar-
macological Experiment Center of Dongzhimen Hospi-
tal, Beijing University of Chinese Medicine, Beijing,
China. They were maintained in a temperature-con-
trolled (24℃ ) pathogen-free vivarium, on a 12:12 h
light: dark cycle (12 h light: 6 am to 6 pm; 12 h dark:
6 pm to 6 am) with free access to food and water. All
experimental procedures were performed under the re-
quirements of the Provision and General Recommenda-
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tions of the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were ap-
proved by the Animal Research Ethics Board of Beijing
University of Chinese Medicine.
Three-month-old APPV717I transgenic mice were ran-
domly divided into ten groups (n=12 per group) and
intragastrically administrated vehicle or medicines:
APP group was given 0.5% CMC, donepezil group
was given donepezil (APP +D group) (0.92 mg/kg-1·
day-1), and GEPT groups were given small dose of GE-
PT (APP + Gs group) (0.075 g/ kg-1·day-1), medium
dose (APP+Gm group) (0.15 g/ kg-1·day-1), and large
dose (APP+Gl group) (0.30 g/ kg-1·day-1) for 4 or 8
months, respectively. Three-month-old C57BL/6J
mice as vehicle controls (n=12) were given 0.5%CMC
for 4 or 8 months as well.
Immunohistochemistry
All behaviorally-tested mice were deeply anesthetized
with 10% chloral hydrate (40 mg/kg body weight, in-
traperitoneal), pericardially perfused with heparinized
0.9% saline, and removed the brain. The right hemi-
spheres were immersion-fixed in 4% paraformaldehyde
overnight at 4℃, and then processed in phosphate buff-
ered saline (PBS) solution containing 30% sucrose. Sev-
en days later, they were embedded in parafine. Serial
coronal sections of the hippocampus were cut at 35 μm
intervals for immunohistochemistry (IHC) staining.
While the left hemisphere was snap frozen for Western
blotting.
These brain sections were deparaffinised and degraded
to distilled water. Antigens were unmasked in 0.01 M
Citrate Buffer (Sun Biomedical Technology Co., Ltd.,
China) by microwave, and endogenous peroxidise activ-
ity was quenched by 0.3% hydrogen peroxide (Sun Bio-
medical Technology Co., Ltd., China) in methanol for
20 min at room temperature. Then the sections were
blocked in 10% antibodies in 3% bull serum albumin/
PBS for 30 min at 37℃ . After excess serum was re-
moved, sections were incubated with the primary anti-
body in humidified boxes at 4℃ overnight (GSK-3β 1∶
500; blocking buffer was used as primary antibody in
the internal control staining). They were washed once
again and incubated with biotin conjugated secondary
antibodies (1∶300; Fuzhou Maixin Ltd., China) at
37℃ for 30 min, and then washed again and incubated
with Streptavidin-Biotin Complex (SABC) (Wuhan
Boster Bioengineering Co., Ltd., China) for 1 h at
37℃ . Subsequently, sections were developed using
chromogen 3'3-diaminobenzidine tetrachloride, dehy-
drated, and affixed with coverslips. All brain sections
chosen for staining were on a similar sagittal plane and
contained approximately the same area of hippocam-
pus. GSK-3β integrated optical density (IOD) was
measured in immunostained sections, following the in-
structions of the Image Pro Plus 6.0 software (Media
Cybernetics Company, MD, USA). "Nonspecific" im-
munological histological chemistry (IHC) staining in
sections was chosen as the control area for comparison
with the GSK-3β-immunopositive area in the neurons
of the dentate gyrus.
Western blotting
Western blots were performed as described previously.14
Briefly, snap-frozen brain tissues from hippocampus
and cortex were weighted and homogenized with brain
tissue lysis buffer (SABC) (Wuhan Boster Bioengineer-
ing Co., Ltd., China) at a ratio of 1∶10 (w/v) by a
small pestle on ice for 2 min and incubated on ice for
30 min. Homogenates were centrifuged at 13 000 rpm
at 4℃ for 30 min, and supernatants were collected.
Protein level in the supernatants was determined by
Bradford method17 using Coomassie Brilliant Blue
G-250 (Nanjing Jiancheng Bioengineering Institute,
China). Loading buffer was added to samples at a ratio
of 4∶1, after which they were placed in boiling water
for 5 min and then chilled immediately on ice. 10 μL
protein/well samples and 5 μL marker (10KD-170
KD) were loaded onto a 10% acrylamide gel (Sig-
ma-Aldrich Co. LLC, St. Louis, USA) and subjected to
sodium dodecyl sulfate polyacrylamide gel electropho-
resis using the Bio-Rad mini gel system (Bio-Rad, CA,
USA). Proteins were then electro-blotted onto a polyvi-
nylidine difluoride membrane. Membranes were
blocked with 5% milk at 4℃ overnight, and then incu-
bated with primary antibody (GSK-3β, ab131356, 1∶
1000). After washing with PBS containing 0.5%
Tween 20 (PBST) (Sun Biomedical Technology Co.,
Ltd., China), for 3 times, membranes were incubated
at room temperature for 1 h with HRP-conjugated sec-
ondary antibody (Promega Co., WI, USA) at 1∶5000
dilutions on a shaker. Blots were developed using the
luminol reagent (Pierce Biotechnology, Inc., France).
Densitometric analysis of the blots was completed us-
ing the Phoretix 1D software (Total Lab Ltd., UK).
Statistical analysis
All data are analyzed by SPSS 13.0 software and pre-
sented as the mean±standard deviation (SD). One-way
ANOVA was used when comparisons were made
among those groups. P<0.05 was considered statistical-
ly significant.
RESULTS
GSK-3β expression levels in 7-month-old
experimental mice
Immunohistochemistry analysis showed a significant
increase of GSK-3β in the brain cortex of 7-months-
old APPV717I transgenic mice as compared with the
control group (P=0.003), while in the donepezil or GE-
PT treated transgenic mice were all significantly de-
creased (APP+D vs APP: P=0.041; APP+Gl vs APP: P=
0.049; APP+Gm vs APP: P=0.029; APP+Gh vs APP:
P=0.036); Among the treatment groups, the GSK-3β
213
JTCM |www. journaltcm. com April 15, 2013 |volume 33 | Issue 2 |
Shi J et al. / Experimental Study
level was significantly higher only in the Gl group than
that in the APP+D group (P=0.043). IHC staining pic-
tures were shown in Figure 1(A-F) and detailed data
were shown in Table 1.
Western blot analysis showed that the density of
GSK-3β expression in APP mice increased significant-
ly (compared to control group, P=0.008). However,
the GSK-3β expression in donepezil or GEPT treated
transgenic mice were all decreased, and there was signif-
icant difference between APP +Gh group or APP +D
group and the APP group (P=0.05). And there was no
significant difference between APP + Gh group and
APP+D group. Representative Western blot bands were
shown in Figure 2A and detailed data were shown in
Figure 2B.
GSK-3β expression levels in11-month-old
experimental mice
Immunohistochemistry analysis showed a increase of
GSK-3β in brain cortex of 11-month-old APPV717I
transgenic mice and C57BL mice (there was no signifi-
cant difference between APP and control group, P=
0.071), while the GSK-3β expression in donepezil or
GEPT treated groups were all significantly decreased
(APP+D vs APP: P=0.031; APP+Gl vs APP: P=0.023;
APP + Gm vs APP: P=0.001; APP + Gh vs APP: P=
0.020); Among treatment group, there were significant
differences between APP+Gm or APP+Gh group and
APP+D group (APP+Gm vs APP+D: P=0.024; APP+
Gh vs APP+D: P=0.036), and the APP+Gm or APP+
Gh group lower than the APP+D group. IHC staining
pictures were shown in Figure 3 (A-F) and detailed da-
ta were shown in Table 1.
Western blot analysis also showed that the density of
GSK-3β in the treatment groups were all significantly
decreased (APP+D vs APP: P=0.021; APP+Gl vs APP:
P=0.017; APP + Gm vs APP: P=0.013; APP + Gh vs
APP: P=0.026). Representative Western blot pictures
were shown in Figure 4A and detailed data were shown
in Figure 4B.
DISCUSSION
GSK-3 has gained a great attention in AD pathogene-
sis research, and it provides a possible link between be-
ta amyloid peptide and tau protein.4,6 Over activity of
GSK-3 can lead to tau hyperphosphorylation and in-
creasing of Aβ was observed in various in vivo and in
vitro models of AD.5-7 In detail, GSK-3β can phosphor-
ylate certain sites on tau and thereby significantly im-
pair tau's ability to bind microtubules. GSK-3β may al-
so play a role in regulating tau degradation8 and insolu-
ble tau fibrils formation.9 And inhibiting GSK-3 activi-
ty could relieve accumulation of Aβ peptides and for-
mation of hyperphosphorylated insoluble tau fibrils in
the best available models of AD,10-12 Thus this research
aimed to investigate the neuroprotective mechanism of
GEPT in treating Alzheimer disease on GSK-3β level.
APPV717I transgenic mice used in this study were of
C57BL/6J genetic background and carried mutated hu-
man APP-CT100 containing the London mutation
V717I, which is characterized by increased generation
of Aβ42 and Alzheimer disease-like pathological chang-
es,18 However, the formation of amyloid plaques only
initiates in APP/V717I transgenic mice around their 9
months old.19,20 In order to investigate the neuroprotect-
ing mechanism of GEPT before and after amyloid
plaques formation, APPV717I transgenic mice aged 3
months were used in our experiment and treated with
GEPT up to their 7 or 11 months. That is, 3 months
old APPV717I transgenic mice were treated by GEPT
extract for 4 or 8 months in this study.
In previous studies, GEPT markedly enhanced learn-
ing and memory function of AD rat model induced by
hippocampal or intravenous injection of Aβ1-42, and
significantly improved spatial learning and memory of
APPV717I transgenic mice during the 8 months' treat-
ment.14,15 Further study shown that GEPT extracts can
reduce levels of endogenous Aβ peptide in the brain of
APPV717I transgenic mice through inhibiting presenil-
in-1 (PS1) activity rather than beta-secretase 1
(BACE1) and promoting IDE and NEP activity.14 And
previous preliminary clinical study also indicated that a
three-month treatment of GEPT had significant effec-
tiveness in improving memory and cognitive impair-
ment and delaying memory decline through one year
in 70 patients with aMCI.21 However, it is unknown
for GSK-3β inhibiting effects of GEPT in APP mice.
GSK-3β was detected in the brain cortex of 7 or
11-month-old experimental mice. The level of
GSK-3β expression in the brain cortex of APPV717I
Table 1 IOD (sum) of GSK-3β in the brain cortex of
7-month-old and 11-month-old mice measured by Immuno-
histochemistry ( xˉ ±s)
Group
Control
APP
APP+D
APP+Gl
APP+Gm
APP+Gh
7-month-old mice
IOD (sum)
87625±5257
125228±10515ab
102027±4381ab
113031±6134abc
98896±8762ab
107244±1752ab
11-month-old mice
IOD (sum)
112080±8966
131704±11208ab
92959±5604ab
82937±7846ab
68591±4483abc
74604±5064abc
Notes: control: C57BL/6J mice group given 0.5% carboxymeth-
yl cellulose; APP: APPV717I transgenic mice group given 0.5%
carboxymethyl cellulose; APP + D: APPV717I transgenic mice
group given donepezil (0.92 mg/kg-1·day-1); APP + Gl: AP-
PV717I transgenic mice group given small dose of GEPT
(0.075 g/kg-1·day-1); APP + Gm: APPV717I transgenic mice
group given medium dose (0.15 g/kg-1·day-1); APP +Gh: AP-
PV717I transgenic mice group given large dose (0.30 g/kg-1·
day-1). IOD: integrated optical density. aP<0.05, compared with
control group; bP<0.05, compared with APP group; cP<0.05,
compared with APP+D group.
214
JTCM |www. journaltcm. com April 15, 2013 |volume 33 | Issue 2 |
Shi J et al. / Experimental Study
transgenic mice was significantly higher than control
group, and the GSK-3β expression of donepezil or GE-
PT treated transgenic mice were all significantly de-
creased compared with APP groups. Among the treat-
ment groups, there were no significant difference be-
tween APP+Gm or APP+Gh group and the APP+D
group. This data indicates that GEPT extract can also
act as a potential GSK-3β inhibiting agent in APP
mice, which can exert before the formation of amyloid
plaques.
In summary, GEPT can effectively decrease the
GSK-3β expression level in the brain cortex of AP-
PV717I transgenic mice. Moreover, this study showed
that the effect of GEPT on GSK-3β in the cerebral cor-
tex of 11 months old mice is more significant than 7
months old mice. It indicates that GEPT could reduce
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Figure 2 Representative Western blot bands of GSK-3β and β-actin detected by Western blotting in 7-month-old mice (A) and da-
ta column analysis (B)
Control: C57BL/6J mice given 0.5% carboxymethyl cellulose; APP: APPV717I transgenic mice group 0.5% carboxymethyl cellulose;
APP+D: APPV717I transgenic mice group donepezil (0.92 mg/kg-1·day-1); APP+Gl: APPV717I transgenic mice given small dose of
GEPT (0.075 g/kg-1·day-1); APP+Gm: APPV717I transgenic mice given medium dose of GEPT (0.15 g/kg-1·day-1); APP+Gh: APPV717I
transgenic mice given large dose of GEPT (0.30 g/kg-1·day-1). GSK-3β: glycogen synthase kinase 3β; INT: intensity. aP<0.05 com-
pared with control group; bP<0.05 compared with APP group; aP<0.05 compared with donepezil group.
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Figure 1 Immunocytochemical staining for GSK-3β in brain cortex of 7-months-old mice (IHC×200, Bar=100 μm)
A: control group; B: APP group; C: APP+D group; D: APP+Gl group; E: APP+Gm group; F: APP+Gh group. Control: C57BL/6J mice
given 0.5% carboxymethyl cellulose; APP: APPV717I transgenic mice group 0.5% carboxymethyl cellulose; APP +D: APPV717I
transgenic mice group donepezil (0.92 mg/kg-1·day-1); APP+Gl: APPV717I transgenic mice given small dose of GEPT (0.075 g/kg-1·
day-1); APP+Gm: APPV717I transgenic mice given medium dose of GEPT (0.15 g/kg-1·day-1); APP+Gh: APPV717I transgenic mice
given large dose of GEPT (0.30 g/kg-1·day-1). GSK-3β: glycogen synthase kinase 3β; IHC: immunological histological chemistry
staining.
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the level of GSK-3β in AD model rats. This partially
explains the neuroprotective mechanism of GEPT in
preventing and treating AD.
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